O besity is associated with elevated levels of the adipokine leptin, 1 whose main function is to regulate appetite and energy homeostasis via central nervous system signaling and leptin receptors (LepR) located on specific neurons within the hypothalamus. 2 The coexistence of increased body weight and elevated circulating leptin levels is thought to be caused by the resistance of the central nervous system to the weight-reducing effects of the hormone. Although the presence of a socalled central leptin resistance is well established, it is unclear whether a cell-specific leptin resistance exists on peripheral cells and how this phenomenon would relate to other, in particular, the cardiovascular effects of the adipokine.
O besity is associated with elevated levels of the adipokine leptin, 1 whose main function is to regulate appetite and energy homeostasis via central nervous system signaling and leptin receptors (LepR) located on specific neurons within the hypothalamus. 2 The coexistence of increased body weight and elevated circulating leptin levels is thought to be caused by the resistance of the central nervous system to the weight-reducing effects of the hormone. Although the presence of a socalled central leptin resistance is well established, it is unclear whether a cell-specific leptin resistance exists on peripheral cells and how this phenomenon would relate to other, in particular, the cardiovascular effects of the adipokine.
We and others have previously shown that systemically or locally elevated leptin levels promote neointima formation, and analysis of db/db mice with systemic LepR deficiency revealed that this effect requires the presence of LepRs. 3, 4 In fact, db/ db mice were protected from intima hyperplasia despite the presence of obesity and leptin resistance, which are established cardiovascular risk factors in humans, but also in mice. LepRs are expressed on various cell types, including endothelial cells (ECs) and smooth muscle cells (SMCs), 5 and studies in cultivated cells revealed that leptin promotes SMC proliferation and migration, 6 a critical event contributing to neointima formation. On the other hand, the role of endothelial LepRs (End.LepRs) during neointima formation is less clear. For example, leptin has been shown to promote angiogenesis, 7 and the restoration of endothelial integrity and secretion of SMC quiescence factors are considered an important mechanism limiting restenosis after vascular injury. In this regard, we have previously shown that exogenous stimulation of human endothelial progenitor cells with leptin followed by their administration into mice after vascular injury enhances their capacity to promote reendothelialization resulting in smaller neointimal lesions. 8 On the basis of these previous observations, we hypothesized that leptin signaling in ECs would have beneficial consequences and protect mice from neointima formation; however, this and the effects of chronic hyperleptinemia in states of obesity have never been directly studied to date.
In this study, we examined the role of leptin signaling in ECs during neointima formation after vascular injury in dietinduced obese mice and mice with inducible, EC-restricted deletion of LepRs to test the hypothesis that obesity represents a state of endothelial resistance to the vascular effects of the adipokine leptin.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Generation of EC-Specific LepR-Deficient Mice
To examine the importance of End.LepR signaling during neointima formation, mice with inducible EC-specific LepR deletion (End.LepR knockout [KO]) were generated. Successful Lepr gene excision was confirmed using PCR analysis of genomic DNA from tail biopsies ( Figure IA .Cre recombinase activity was examined in endothelial reporter mice after induction by tamoxifen feeding. Immunofluorescence confocal microscopy confirmed GFP (green fluorescent protein) expression (and thus Cre recombinase activity) restricted to ECs lining the vascular lumen ( Figure IIA in the online-only Data Supplement). Flow cytometry analysis (n=3 independent experiments) of GFP expression in whole blood and bone marrow revealed that <0.5% of all cells in both hematopoietic compartments expressed the GFP reporter, that is, 0.1±0.06% in blood and 0.07±0.03% in bone marrow ( Figure IIB in the online-only Data Supplement).
Abolished Endothelial Leptin Signaling in End.LepR-KO Mice
To confirm the absence of endothelial leptin signaling in End. LepR-KO mice, mPECs were isolated and LepR signaling in response to leptin examined using signal transducer and activator of transcription-3 (STAT3) phosphorylation as surrogate marker. Significantly increased levels of phosphorylated STAT3 (at Tyr705 and Ser727) after stimulation with recombinant murine leptin (10 ng/mL for 15 minutes) were observed in mPECs isolated from End.LepR-WT mice, but not in those from End.LepR-KO mice ( Figure 1A and 1B, representative findings are shown in Figure 1C ). Moreover, mPECs from End.LepR-KO mice exhibited significantly reduced basal protein levels of suppressor of cytokine signaling (SOCS)-3 ( Figure 1D and 1G), a surrogate marker of leptin-induced STAT3 activation. 9 Protein expression of protein tyrosine phosphatase (PTP)-1B ( Figure 1E and 1G) and of phosphatase and tensin homolog (PTEN; Figure 1F and 1G), that is, phosphatases involved in leptin resistance, 10 was also significantly reduced in mPECs from End.LepR-KO mice.
Deletion of End.LepRs Results in Increased Neointima Formation
The importance of End.LepR signaling for the vascular response to injury was examined in lean and high-fat diet (HFD) obese mice using 10% FeCl 3 . Of note, End.LepR-WT and End.LepR-KO mice exhibited similar mean times to thrombotic occlusion (7.0±0.5 versus 6.8±0.3 minutes; P=0.635). Morphometric analysis of vascular lesions 3 weeks after induction of injury revealed that End.LepR deletion was associated with a significant increase in the neointima area (Figure 2A ), intima-to-media ratio ( Figure 2B ), and lumen stenosis ( Figure 2C ) compared with End.LepR-WT mice. Similar changes were observed in End.LepR-WT mice with diet-induced obesity, and findings did not differ from those observed in lean mice lacking End.LepRs. On the other hand, End.LepR deletion did not affect the media ( Figure 2D ) and total vessel area ( Figure 2E) Figure 2F ). Feeding End.LepR-KO mice with HFD resulted in a further significant increase in neointima size, both compared with End.LepR-KO mice fed normal chow and End.LepR-WT mice fed HFD (Figure 2A through 2C ). Representative images of neointimal lesions after Verhoeff elastic stain ( Figure 2G , top) or immunohistochemistry for α-smooth representative findings in Figure VF in the online-only Data Supplement). Induction of obesity with HFD in these mice resulted in a significant increase in neointima and media area, intima-to-media ratio, and total vessel area, independent of the SMC.LepR genotype (Figure VA through VF in the onlineonly Data Supplement).
Altered Paracrine Effects of ECs on SMC Proliferation in End.LepR-KO Mice
The endothelium plays an important role in the paracrine control of SMC function. We therefore examined the effects of medium conditioned (CdM) with mPECs isolated from End. LepR-WT or End.LepR-KO mice on coincubated murine aortic SMCs (MOVAS). These analyses revealed a significantly reduced capacity of mPEC-CdM from End.LepR-KO mice to control MOVAS proliferation, as shown by the significantly higher mRNA expression of cyclin D1 compared with CdM from End.LepR-WT mice ( Figure Figure VIC in the online-only Data Supplement). In line with these in vitro findings, End.LepR deletion was associated with a significant increase in the number of total cell nuclei in the neointima compared with lean End.LepR-WT mice ( Figure 3A ), whereas cell numbers in the media did not differ ( Figure 3B ). Similar findings were observed after immunohistochemical quantification of the proliferation marker PCNA (proliferating cell nuclear antigen; Figure 3C and 3D).
Diet-induced obese End.LepR-WT mice also exhibited a significantly increased lesion cellularity ( Figure 3A and 3B) and number of proliferating cells in the neointima ( Figure 3C and 3D). Representative findings after PCNA immunostaining are shown in Figure 3E .
Endothelial Leptin Resistance in Obesity
The similarities in the vascular remodeling response to injury between obese End.LepR-WT and lean End.LepR-KO mice suggested that the enhanced neointima formation in dietinduced obesity is the result of impaired LepR signaling in ECs. Reverse transcriptase polymerase chain reaction analysis revealed significantly increased LepR mRNA levels in mPECs isolated from obese hyperleptinemic End.LepR-WT mice ( Figure VIIA and VIIB in the online-only Data Supplement). Western blot analysis confirmed increased LepR protein levels in mPECs isolated from obese mice and in those isolated from lean mice in response to leptin stimulation ( Figure VIIC and VIID in the online-only Data Supplement). Moreover, significantly elevated soluble LepR levels were observed in serum of obese End.LepR-WT mice resulting in a significantly reduced calculated free (ie, active) leptin index, a finding not observed in End.LepR-KO mice fed HFD (Table) . Basal expression levels of phosphorylated STAT3 (P<0.05 for p-STAT-Tyr705 and P<0.05 for p-STAT-Ser727; Figure 4A , 4B, and 4F), SOCS-3 (P=n.s.; Figure 4C and 4F), PTP-1B (P<0.05; Figure 4D and 4F), and PTEN (P<0.01; Figure 4E and 4F) were elevated in obese compared with lean mPECs isolated End.LepR-WT mice in line with chronically activated leptin signaling, but did not increase further in response to exogenous leptin, suggesting that obesity results in endothelial leptin resistance. 
Expression of Smooth Muscle Mitogens in LepR-Deficient and Leptin-Resistant EC
Quantitative real-time PCR was used to examine mPECs isolated from End.LepR-KO and obese End.LepR-WT mice for the mRNA expression of mediators known to promote SMC proliferation and neointima formation. These analyses revealed that ECs of End.LepR-KO mice expressed significantly increased mRNA levels of endothelin-1 (ET-1; Figures 5A and 6A), and significantly higher mean ET-1 mRNA levels were also observed in mPECs from obese End.LepR-WT mice ( Figures 5B and 6A ). The results of these analyses also suggested endothelial activation, particularly in mPECs isolated from obese End.LepR-WT mice, which was confirmed by significantly increased mRNA levels ( Figure 5B ) and endothelial expression ( Figure 5C ) of ICAM2 (intercellular adhesion molecule-2) and COX2 (cyclooxygenase-2), whereas mRNA levels of PPAR-γ (peroxisome proliferator-activated receptor-γ) were significantly reduced ( Figure 5A and 5B). On the other hand, VEGF (vascular endothelial growth factor) mRNA levels were significantly reduced in mPECs from End.LepR-KO mice ( Figure 5A ), whereas mRNA levels of endothelial NO synthase, inducible NO synthase, COX1 (cyclooxygenase-1), FGF2
(fibroblast growth factor-2), PDGF (platelet-derived growth factor), and TGF-β (transforming growth factor-β) did not significantly differ from their respective controls, neither in LepRdeficient ( Figure 5A ) nor in obese ( Figure 5B ) mPECs. Analysis of CdM with mPEC revealed a similar low (below the detection limit of 1.56 µmol/L) release of nitric oxide (NO; as determined by measurement of the primary stable product nitrite). Prostacyclin levels in CdM also did not differ in mPEC-CdM from End.LepR-KO (7801±2765 versus 9530±3011 ng/mL in CdM-End.LepR-WT; P=0.675) or from End.LepR-WT+HFD mice (8529±732 versus 9580±1254 ng/mL; P=0.496). Elevated ET-1 levels were confirmed using ELISA of CdM of mPECs isolated from End.LepR-KO compared with End.LepR-WT mice ( Figure 6B ). Moreover, a higher percentage of endothelium lining the uninjured carotid artery lumen of End.LepR-KO and obese End.LepR-WT mice was immunopositive for ET-1 ( Figure 6C , representative immunofluorescence images are shown in Figure 6E ), and an increased relative ET-1-immunopositive area was also present in the media ( Figure 6D and 6E) . Significantly increased vascular ET-1 expression was also detected in neointimal lesions of End.LepR-KO and End.LepR-WT+HFD mice (Figure 11 Importantly, the functional effects of CdM from End.LepR-KO mice on MOVAS in terms of increased proliferation were significantly reduced to levels observed in CdM from End.LepR-WT mPECs if MOVAS were preincubated with the ET receptor A/B antagonist PD145065 ( Figure 6F ). These in vivo, ex vivo, and in vitro findings suggest that an increased release of ET-1 and paracrine stimulation of EC and SMC proliferation contributes to the observed enhanced neointimal hyperplasia in mice with End.LepR deletion. Underscoring the clinical relevance of our findings, obese individuals exhibited significantly increased serum ET-1 levels compared with lean controls ( Figure 6G ).
To examine possible mechanisms underlying the observed increase in ET-1 expression in ECs lacking LepRs, further experiments were performed. The ET-1 promoter contains a proximal activator protein-1 (AP-1) binding site, 12 and previous in vitro studies have shown that leptin promotes ET-1 expression via mechanisms involving AP-1. 13 Immunofluorescence confocal analysis of c-jun, a subunit of the AP transcription factor, confirmed an increased number of cells with nuclear c-jun localization in End.LepR-WT mPECs stimulated with leptin (10 ng/mL for 1 hour), and similar findings were observed in mPECs from End.LepR-KO mice, independent of exogenous leptin ( Figure 7A ; quantitative analysis in Figure 7B ). AP-1 itself may be negatively regulated by PPAR-γ by preventing AP-1 binding to the ET-1 promoter.
14 To examine if the significantly lower PPAR-γ expression observed in mPECs from both LepR-deficient and leptin-resistant obese mPECs may have played a role, human umbilical vein ECs were treated with the PPAR-γ antagonist T0070907. As shown in Figure 8 , PPAR-γ antagonization was associated with an increased nuclear localization of c-jun ( Figure 8A ; quantitative analysis in Figure 8B ) and also resulted in increased ET-1 protein expression levels ( Figure 8C ) at all concentrations tested (1, 10, and 25 µmol/L for 24 hours). These analyses suggest that reduced expression of PPAR-γ may underlie the observed 
Discussion
Obesity is associated with elevated serum leptin levels and resistance to the central (ie, appetite and body weight controlling) effects of the adipokine. Elevated serum leptin levels have been associated with an increased cardiovascular risk, and experimental studies demonstrated that exogenous leptin promotes neointima formation. However, it is unclear whether the more pronounced neointima formation observed in the obese develops as consequence of the chronic hyperleptinemia and activated leptin signaling or is the result of vascular leptin resistance.
In this study, we show that reduced expression of LepRs and abrogation of leptin signaling in ECs results in intimal hyperplasia, increased neointima cellularity, and paracrine stimulation of arterial SMC proliferation. A similar vascular phenotype was observed in WT mice fed HFD, suggesting that obesity results in functional End.LepR deficiency, and analyses of primary ECs from obese mice confirmed this conclusion by showing abrogated leptin-induced STAT3 phosphorylation. Effect of murine endothelial leptin receptor (End.LepR) deficiency and leptin stimulation on nuclear localization of c-jun. Primary murine endothelial cells (mPECs) were isolated from mouse lungs (n=3 mice per group) and cultivated as described in the Materials and Methods followed by the stimulation with murine recombinant leptin (10 ng/mL for 1 h) or control (equal volume of phosphate-buffered saline). The intracellular localization of c-jun, a subunit of the transcription factor activator protein-1 (AP-1), was determined using immunocytochemistry and confocal microscopy (the second and the fourth rows represent magnifications of images shown in the first and the third rows, respectively). Endothelial cell identity was confirmed using antibodies against CD31. Representative images in mPECs isolated from End.LepR-WT and End.LepR-KO mice are shown in (A), the results of the quantitative analysis of cells showing nuclear localization of c-jun in (B). *P<0.05 and **P<0.01. Broken white lines highlight cell nuclei. Size bars represent 25 µm.
Our finding that deletion of LepRs in SMCs did not affect neointima size or lumen stenosis further supports the critical role of intact endothelial leptin signaling in controlling vascular lesion formation. In contrast to End.LepR-deficient animals, a significantly enhanced medial hyperplasia was observed in mice lacking LepRs in SMCs, similar to obese WT mice, suggesting that the vascular phenotype in obesity represents a combination of endothelial and smooth muscle leptin resistance. Arterial SMCs from obese LepR-WT mice also did not respond to leptin stimulation ( Figure X in the online-only Data Supplement) and exhibited an increased baseline proliferation and migration, suggesting that leptin resistance and other factors underlie the media hyperplasia observed in obese mice.
LepRs are expressed on diverse vascular cell types, including ECs and SMCs. 5, 15 We have previously shown that exogenous administration of recombinant leptin >3 weeks after vascular injury (mimicking the hyperleptinemia observed in obesity) results in increased neointima formation, whereas intima hyperplasia did not develop in obese leptin-deficient ob/ob mice. 3 Underlining the importance of the leptin-LepR axis for neointima formation, leptin failed to promote neointima hyperplasia in db/db mice lacking LepRs in all cells, 3, 4 and others also reported protection of db/db mice and leptindeficient ob/ob from intimal hyperplasia. 16, 17 Potential explanations for these seemingly contradictory findings may include differences in circulating leptin levels between cellspecific (unchanged) and global LepR-deficient mice (highly elevated). 18 In addition, it is possible that leptin continues to signal via its receptors present on other cell types involved in neointima formation, such as inflammatory cells or platelets. Nevertheless, mice with cell-specific deficiency of LepRs offer the unique opportunity to differentiate the vascular effects of the adipokine from those of obesity itself, in contrast to mice with systemic deficiency of leptin or its receptor, whose phenotype is unavoidably complicated by the presence of obesity and the associated metabolic and inflammatory alterations.
Reconstitution of endothelial integrity is critical for the attenuation of intimal hyperplasia by preventing platelet or leukocyte adhesion and inducing SMC quiescence. On the effects of leptin on ECs, we and others have shown that leptin promotes endothelial (progenitor) cell proliferation, migration, and angiogenesis. 7, 19, 20 Moreover, exogenous stimulation of human endothelial progenitor cells with leptin before injection into athymic mice enhanced endothelial progenitor cell recruitment to the site of vascular injury, improved re-endothelialization, and attenuated neointima formation. 8 Although acute leptin stimulation seems to promote endothelial function, studies in cultivated ECs have shown that chronic exposure to leptin induces leptin resistance. For example, prolonged exposure of human aortic ECs to leptin failed to increase endothelial NO synthase expression, phosphorylation, or NO release, 21 and we have shown that obesity results in the resistance of human endothelial progenitor cells to leptin's proangiogenic effects. 19 Clinical studies have observed that obesity is associated with significantly higher risk to develop restenosis, 22 and high serum leptin levels were inversely correlated with endothelial function. 23 However, the existence of a leptin resistance in vivo and its contribution to vascular disease in obesity remains unclear because any direct effects of impaired leptin signaling are difficult to dissect from other alterations associated with increased body weight. Several studies suggested that leptin resistance develops in a cellspecific manner. For example, platelets isolated from lean and obese individuals were found to remain responsive to elevated leptin. 24 Similarly, another study found the sympathoexcitatory actions of leptin to be preserved despite resistance to the satiety and weight-reducing actions of the hormone. 25 The results of the present study suggest that obesity results in endothelial leptin resistance, defined by the inability of leptin to induce leptin signaling, as shown by the absence of increased STAT3 phosphorylation in obese mPECs in response to leptin and the similar vascular phenotype in response to injury in mice lacking End.LepRs.
The mechanisms underlying leptin resistance in obesity are not fully understood and include impaired leptin bioavailability because of increased levels of leptin antagonists (eg, soluble LepRs) or downregulation of LepRs and defective leptin transport across the blood-brain barrier. 26 Significantly elevated serum leptin but also soluble LepR levels were detected in obese End.LepR-WT mice in our study resulting in a reduced free leptin index. Of note, leptin levels even further elevated in serum of End.LepR-KO mice fed HFD, as reported previously, and found to develop secondary to reduced cellular leptin uptake. 27 Although it is possible that these elevated endogenous leptin levels and the increase in visceral adipose tissue mass may have contributed to the phenotype observed in obese End.LepR-KO mice, a highly significant increase in neointima formation was already observed in End.LepR-KO mice fed normal chow, which did not differ with regard to visceral adipose tissue weights and leptin levels from their End.LepR-WT counterparts.
On the other hand, the increase in circulating soluble LepR levels observed in End.LepR-WT+HFD mice was absent in End.LepR-KO mice, in line with their supposed origin after shedding of membrane LepRs. 28 On the molecular level, overexpression of negative feedback regulators of leptin signaling may also play a role, and we have previously shown that leptin resistance is associated with elevated endothelial PTP-1B protein levels, whereas weight loss reduced PTP-1B expression and restored endothelial responsiveness to leptin. 19 In the present study, we found increased levels of PTP-1B and PTEN in mPECs isolated from obese mice, that is, negative regulators of JAK2 (Janus kinase-2) and PI3K/AKT (phosphoinositide 3-kinase/protein kinase B) signaling, respectively. 10 Other factors involved in leptin resistance include overexpression of SOCS-3 29 ; however, SOCS-3 protein levels in ECs isolated from obese mice did not differ significantly from those in their lean counterparts.
To determine the mediators involved in the altered paracrine effects of LepR-deficient and leptin-resistant ECs during neointima formation, the expression of endothelium-derived factors known to promote SMC proliferation was studied. These analyses revealed significantly elevated mRNA expression levels of ET-1, an EC-derived vasoactive peptide involved in the auto-and paracrine regulation of vascular tone and SMC proliferation, in mPECs isolated from End.LepR-KO and HFD-induced obese End. LepR-WT mice. Previous in vitro studies have shown that ET-1 stimulates SMC proliferation 30 and potentiates the effects of other growth factors, such as PDGF, FGF2, or EGF (epidermal growth factor). 31, 32 The blunted response of MOVAS to CdM with primary ECs from End.LepR-KO mice in the presence of an ET receptor A/B antagonist supported a role for ET-1 as paracrine mediator underlying the increased SMC proliferation and neointima cellularity observed in this study. The absence of differences of CdM from End.LepR-WT and End.LepR-KO mice on SMC migration may be explained by the previous observation that ET-1 does not influence migratory behavior of arterial SMCs. 33 Although ET-1 is a potent vasoconstrictor, we did not observe differences with regard to systemic blood pressure, and serum ET-1 levels were similar in End.LepR-WT and End.LepR-KO mice (not shown). In a mouse model with endothelial-restricted ET-1 overexpression, no significant differences in 24-hour blood pressure measurements were observed between WT and endothelial ET-1 transgenic mice. 34 Earlier studies have shown that ET-1 produced in ECs is primarily released to the basolateral cell compartment 35 and also in our study may have acted preferentially on SMCs to induce proliferation. Our conclusion that the increased neointima formation in mice with End.LepR deletion may be the result of increased endothelial ET-1 release is supported by previous studies showing that exogenous ET-1 administration dose dependently enhances neointima formation, 36 whereas antagonization of ET receptors effectively reduced intimal hyperplasia in experimental models of vascular injury. [37] [38] [39] Furthermore, deletion of ET-1 selectively in ECs was shown to reduce neointima formation, vascular adhesion molecule expression, and SMC proliferation, 40 whereas endothelial ET-1 overexpression was associated with vascular hypertrophic remodeling and endothelial dysfunction. 34 Increased local ET-1 expression has been reported in human coronary atherosclerotic plaques, 41 and higher ET-1 and ET-1 receptor expression levels, particularly in ECs, has been described in human atherosclerotic lesions. 42 On the other hand, ET receptor B deletion in SMCs did not alter neointima formation induced by femoral artery injury in mice, 43 in line with the observed absence of differences in media size between End.LepR-WT and End.LepR-KO mice. In patients, ET-1 levels in the coronary sinus were found to be significantly elevated in patients developing restenosis. 44 Interestingly, significantly increased ET-1 expression levels were not only observed in mPECs isolated from End.LepR-KO, but also in those from obese mice supporting the hypothesis that functional endothelial leptin resistance and ET-1 overexpression contribute to the vascular phenotype in obesity. Previous studies reported higher plasma ET-1 levels in obese men, 45 and weight loss was associated with a reduction of elevated plasma ET-1 levels. 46 Although elevated ET-1 levels have been implicated in altered vascular reactivity, the role of ET-1 and vascular ET-1 overexpression for the increased propensity to develop restenosis in obesity has not been examined to date. Our findings are also consistent with endothelial dysfunction, particularly in the obese, and mPECs from obese mice (and also those from End.LepR-KO mice) exhibited reduced mRNA levels of PPAR-γ involved in the suppression of endothelial adhesion molecules. 47 Moreover, our analyses in primary mouse ECs and human umbilical vein endothelial cells suggested that reduced endothelial expression of PPAR-γ, a negative regulator of the AP-1 transcription factor, 14 may have contributed to the increased ET-1 mRNA and protein expression observed in LepR-deficient and leptin-resistant murine ECs.
The observed phenotype may also be explained by a reduced release of quiescence factors, such as NO known to inhibit SMC proliferation, 48 and previous studies have shown that leptin activates endothelial NO synthase. 49 However, undetectable amounts of endothelial NO were released from End.LepR-WT and End.LepR-KO mouse ECs, and endothelial NO synthase immunostaining of uninjured carotid arteries also did not suggest differences. On the other hand, mRNA levels of VEGF, a leptin target gene known to promote SMC proliferation and migration, 50 were reduced in End.LepR-KO mice. Of note, we performed a targeted analysis of endothelial mediators with known paracrine effects on SMCs and regulated by leptin and thus cannot exclude that we may have missed additional important factors.
In conclusion, our findings suggest that the neointima hyperplasia observed in obesity and systemic hyperleptinemia develops as consequence of endothelial leptin resistance. End.LepRs or endothelial-derived factors, such as ET-1, involved in mediating the vascular effects of obesity may represent a therapeutic target to control SMC proliferation after vascular injury and thus the vascular complications of obesity.
